Study: NCT02878161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate(necessary)
Description: Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate(necessary)
Description: Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate(necessary)
Description: Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infliximab :intravenous injection 200mg,every times,0,2,6,14week ,4 times)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Etanercept :hypodermic injection,25mg/twice a week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab:hypodermic injection,40mg/twice a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide (permitted, not necessary)
Description: LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide (permitted, not necessary)
Description: LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide (permitted, not necessary)
Description: LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs (permitted,not necessary)
Description: NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs (permitted,not necessary)
Description: NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs (permitted,not necessary)
Description: NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (permitted,not necessary)
Description: Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (permitted,not necessary)
Description: Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (permitted,not necessary)
Description: Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.